TY - JOUR
T1 - Metastatic Colorectal Cancer
T2 - A Systematic Review of the Value of Current Therapies
AU - Goldstein, Daniel A.
AU - Zeichner, Simon B.
AU - Bartnik, Catherine M.
AU - Neustadter, Eli
AU - Flowers, Christopher R.
N1 - Publisher Copyright:
© 2016 Elsevier Inc.
PY - 2016/3/1
Y1 - 2016/3/1
N2 - To evaluate, from a US payer perspective, the cost-effectiveness of treatment strategies for metastatic colorectal cancer (mCRC), we performed a systematic review of published cost-effectiveness analyses. We identified 14 papers that fulfilled our search criteria and revealed varying levels of value among current treatment strategies. Older agents such as 5-fluorouracil, irinotecan, and oxaliplatin provide high-value treatments. More modern agents targeting the EGFR or VEGF pathways, such as bevacizumab, cetuximab, and panitumumab, do not appear to be cost-effective treatments at their current costs. The analytical methods used within the papers varied widely, and this variation likely plays a significant role in the heterogeneity in incremental cost-effectiveness ratios. The cost-effectiveness of current treatment strategies for mCRC is highly variable. Drugs recently approved by the US Food and Drug Administration for mCRC are not cost-effective, and this is primarily driven by high drug costs.
AB - To evaluate, from a US payer perspective, the cost-effectiveness of treatment strategies for metastatic colorectal cancer (mCRC), we performed a systematic review of published cost-effectiveness analyses. We identified 14 papers that fulfilled our search criteria and revealed varying levels of value among current treatment strategies. Older agents such as 5-fluorouracil, irinotecan, and oxaliplatin provide high-value treatments. More modern agents targeting the EGFR or VEGF pathways, such as bevacizumab, cetuximab, and panitumumab, do not appear to be cost-effective treatments at their current costs. The analytical methods used within the papers varied widely, and this variation likely plays a significant role in the heterogeneity in incremental cost-effectiveness ratios. The cost-effectiveness of current treatment strategies for mCRC is highly variable. Drugs recently approved by the US Food and Drug Administration for mCRC are not cost-effective, and this is primarily driven by high drug costs.
KW - Chemotherapy
KW - Colorectal cancer
KW - Cost-effectiveness
KW - Incremental cost effectiveness ratio
KW - Value
UR - http://www.scopus.com/inward/record.url?scp=84960116482&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84960116482&partnerID=8YFLogxK
U2 - 10.1016/j.clcc.2015.10.002
DO - 10.1016/j.clcc.2015.10.002
M3 - Review article
C2 - 26541320
AN - SCOPUS:84960116482
SN - 1533-0028
VL - 15
SP - 1
EP - 6
JO - Clinical colorectal cancer
JF - Clinical colorectal cancer
IS - 1
ER -